The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis
Abstract Background Sentinel lymph node biopsy (SLNB) is performed to guide recommendations on adjuvant treatments for invasive breast cancer. However, studies have shown oncological safety without SLNB in low-risk patients. We aimed to determine the clinical benefits of delaying SLNB (d-SLNB), if u...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-08-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03344-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234708853948416 |
|---|---|
| author | Albin Bengtsson Karolina Larsson Kian Chin |
| author_facet | Albin Bengtsson Karolina Larsson Kian Chin |
| author_sort | Albin Bengtsson |
| collection | DOAJ |
| description | Abstract Background Sentinel lymph node biopsy (SLNB) is performed to guide recommendations on adjuvant treatments for invasive breast cancer. However, studies have shown oncological safety without SLNB in low-risk patients. We aimed to determine the clinical benefits of delaying SLNB (d-SLNB), if upfront axillary staging was omitted in patients with low-risk invasive breast cancers. Methods and materials A retrospective hypothetical simulated analysis. Patients who had breast surgery and SLNB between 2019 and 2021 were included. Patients with low-risk invasive cancers were identified based on preoperative histopathology (≥ 65 years, Luminal A-like, T1, cN0, Grade 1–2). Outcome analyses were based on the Actual clinical management compared to two different hypothetical Scenarios: (A) upfront SLNB omission only, and (B) upfront SLNB omission with d-SLNB. Primary endpoints were proportion of patients suitable for SLNB omission, outcome of d-SLNB and changes in adjuvant treatments. Secondary endpoint was surgical costs. Result Of 712 patients, 205 (30%) had low-risk invasive cancers and eligible for SLNB omission. In Scenario A, 25 (12%) patients with SLN metastases would have understaged. If Scenario B was applied, the false negative rate of axillary staging would reduce from 25 (12%) to 12 (6%) patients, p < 0.001. On average, adjuvant treatments were given to 73% (Actual clinical setting) vs. 27% (Scenario A) vs. 55% (Scenario B), p < 0.001. Based on 100 patients, d-SLNB was associated with an incremental cost of 55,000 EUR per 100 patients. Conclusion Although upfront SLNB omission was associated with missed SLN metastases, majority of low-risk invasive cancers were SLN negative. Delayed-SLNB could provide additional useful information to guide adjuvant treatments. |
| format | Article |
| id | doaj-art-a4d8859a1e3f4f79a9905e2a21ce7b4c |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-a4d8859a1e3f4f79a9905e2a21ce7b4c2025-08-20T04:03:03ZengSpringerDiscover Oncology2730-60112025-08-0116111210.1007/s12672-025-03344-yThe outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysisAlbin Bengtsson0Karolina Larsson1Kian Chin2Department of Surgery, Kungälv HospitalDepartment of Oncology, Sahlgrenska University HospitalDepartment of Surgery, Sahlgrenska University HospitalAbstract Background Sentinel lymph node biopsy (SLNB) is performed to guide recommendations on adjuvant treatments for invasive breast cancer. However, studies have shown oncological safety without SLNB in low-risk patients. We aimed to determine the clinical benefits of delaying SLNB (d-SLNB), if upfront axillary staging was omitted in patients with low-risk invasive breast cancers. Methods and materials A retrospective hypothetical simulated analysis. Patients who had breast surgery and SLNB between 2019 and 2021 were included. Patients with low-risk invasive cancers were identified based on preoperative histopathology (≥ 65 years, Luminal A-like, T1, cN0, Grade 1–2). Outcome analyses were based on the Actual clinical management compared to two different hypothetical Scenarios: (A) upfront SLNB omission only, and (B) upfront SLNB omission with d-SLNB. Primary endpoints were proportion of patients suitable for SLNB omission, outcome of d-SLNB and changes in adjuvant treatments. Secondary endpoint was surgical costs. Result Of 712 patients, 205 (30%) had low-risk invasive cancers and eligible for SLNB omission. In Scenario A, 25 (12%) patients with SLN metastases would have understaged. If Scenario B was applied, the false negative rate of axillary staging would reduce from 25 (12%) to 12 (6%) patients, p < 0.001. On average, adjuvant treatments were given to 73% (Actual clinical setting) vs. 27% (Scenario A) vs. 55% (Scenario B), p < 0.001. Based on 100 patients, d-SLNB was associated with an incremental cost of 55,000 EUR per 100 patients. Conclusion Although upfront SLNB omission was associated with missed SLN metastases, majority of low-risk invasive cancers were SLN negative. Delayed-SLNB could provide additional useful information to guide adjuvant treatments.https://doi.org/10.1007/s12672-025-03344-yBreast cancerLuminal A-like cancerSentinel lymph node biopsyAxillary lymph node dissectionMetastasesRadiotherapy |
| spellingShingle | Albin Bengtsson Karolina Larsson Kian Chin The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis Discover Oncology Breast cancer Luminal A-like cancer Sentinel lymph node biopsy Axillary lymph node dissection Metastases Radiotherapy |
| title | The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis |
| title_full | The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis |
| title_fullStr | The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis |
| title_full_unstemmed | The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis |
| title_short | The outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low-risk invasive breast cancers: a retrospective hypothetical simulated analysis |
| title_sort | outcome of selective delayed sentinel lymph node biopsy following upfront omission of axillary staging in low risk invasive breast cancers a retrospective hypothetical simulated analysis |
| topic | Breast cancer Luminal A-like cancer Sentinel lymph node biopsy Axillary lymph node dissection Metastases Radiotherapy |
| url | https://doi.org/10.1007/s12672-025-03344-y |
| work_keys_str_mv | AT albinbengtsson theoutcomeofselectivedelayedsentinellymphnodebiopsyfollowingupfrontomissionofaxillarystaginginlowriskinvasivebreastcancersaretrospectivehypotheticalsimulatedanalysis AT karolinalarsson theoutcomeofselectivedelayedsentinellymphnodebiopsyfollowingupfrontomissionofaxillarystaginginlowriskinvasivebreastcancersaretrospectivehypotheticalsimulatedanalysis AT kianchin theoutcomeofselectivedelayedsentinellymphnodebiopsyfollowingupfrontomissionofaxillarystaginginlowriskinvasivebreastcancersaretrospectivehypotheticalsimulatedanalysis AT albinbengtsson outcomeofselectivedelayedsentinellymphnodebiopsyfollowingupfrontomissionofaxillarystaginginlowriskinvasivebreastcancersaretrospectivehypotheticalsimulatedanalysis AT karolinalarsson outcomeofselectivedelayedsentinellymphnodebiopsyfollowingupfrontomissionofaxillarystaginginlowriskinvasivebreastcancersaretrospectivehypotheticalsimulatedanalysis AT kianchin outcomeofselectivedelayedsentinellymphnodebiopsyfollowingupfrontomissionofaxillarystaginginlowriskinvasivebreastcancersaretrospectivehypotheticalsimulatedanalysis |